Purpose of this research was to find specific characteristics angiographic lesions appropriate for intracranial percutaneous transluminal cerebral angioplasty (PTCBA). Forty-two clinically symptomatic patients with 42 haemodynamically significant intracranial lesions were treated by PTCBA between January 1992 and May 1996. Before the angioplasty treatment, the patients were classified into three groups according to angiographic lesion characteristics. They were followed after PTCBA from one month to six years to compare the three groups. Primary end points were death, stroke, or bypass surgery. The clinical success rates in type A, B and C groups were 92%, 86% and 33% (p=0.0032), respectively. Cumulative risks of fatal or nonfatal ischaemic stroke in type A, Band C groups were 8%, 12% and 56%, respectively. PTCBA fo r intracranial simple (type A) lesions produces a favourable clinical outcome for symptomatic patients.
Introduction
Main cause of cerebrovascular death was an ischaemic stroke and its mortality rate remains high in Kochi prefecture. Percutaneous transluminal angioplasty (PTA) has been shown to be of value in decreasing ischaemic symptoms and improving perfusion to the coronary and other peripheral vessels in the past 30 years. However, it has not been until the past few years that percutaneous transluminal cerebral balloon angioplasty (PTCBA) of the intracranial artery has been reported 1 -4. In general, transluminal dilatation of small and fragile intracranial arteries appears to be more dangerous than that of the extracranial, coronary or other peripheral arteries. A previous study has reported that a short, concentric or mild eccentric and not angulated intracranial arterial stenosis may be appropriate to initial or repeated PTCBA 5 • In the present study, therefore, the purpose was to assess the safety and efficacy of initial and elective cerebral angioplasty, to investigate the clinical outcome, and finally to determine the subgroup appropriate to PTCBA amongst three groups classified by angiographic lesions' characteristics prior to PTCBA.
Materials and Methods
Clinically symptomatic patients underwent PTCBA and their prognosis was followed thereafter from one month to six years. Inclusion criteria for the study were (1) haemodynamically significant stenosis of one of the following major intracranial arteries: the distal internal carotid artery (DICA), the middle cerebral artery (MCA), the distal vertebral artery (DVA), the basilar artery (BA) and the posterior cerebral artery (PCA); (2) recurrent or crescendo transient ischaemic attacks (TIAs) unresponsive to maximal medical therapy, or a minor stroke with persistence of symptoms or signs in the distribution of the stenotic artery; and (3) patients within 6 months from the last attack.
Exclusion criteria were as follows: (1) patients with prior intracranial PTCBA; (2) patients in the acute stroke stage; (3) patients with a severe neurological deficit from a major stroke; ( 4) patients presenting total occlusion older than 6 months; (5) patients with chronic total occlusion that were longer than 10 mm in length, and (6) patients presenting chronic total occlusion without visible distal segment on angiograms.
A total of 61 consecutive PTCBAs for the m-Symposium Neuroradiologicum XVI tracranial artery were performed in 61 patients between January 1992 and May 1996 in the authors' institute. Twelve patients with prior intracranial PTCBA and 7 patients with PTCBA in the acute stroke stage were excluded from further analysis. Forty-two patients (33 men and 9 women) aged 4 to 76 years were therefore analysed. The mean age of the patients was 59 years (±13). Lesions involved the DICA in 8 patients, the MCA in 21 patients, the DVA in 6 patients, the BA in 5 patients and the PCA in 2 patients. All patients, except the boy, received 81-162 mg of acetylsalicylic acid (aspirin: ASA) per day approximately one week before and after PTCBA.
Anticipation of the likelihood of a successful procedure is required before performing PTCBA. Cerebral angiographic classification described elsewhere 5 summarised the length and geometry of lesions as follows: type A, a short (5 mm or less in length) concentric or moderately eccentric lesions less than totally occlusive; type B, a tubular lesion (5-10 mm in length), an extreme eccentric lesion or total occlusion < 3 months old; and type C, a diffuse lesion (more than 10 mm in length), an extremely angulated (> 90°) lesion, a lesion with excessive tortuosity of proximal segment or total occlusion 3 months or older.
Before PTCBA, patients were neurologically assessed and after PTCBA monitored every month at an outpatient clinic and neurological status examined by the neurosurgeon. Patients with clinically successful dilatation underwent arteriographic follow-up 3 and 12 months later 5. Angiographic restenosis was defined as 50% or greater diameter stenosis at the follow-up.
When symptoms due to restenosis or new lesions occurred or SPECT scans demonstrated impairment of vascular reserve, ECIIC bypass surgery or PTCBA was performed.
The primary end point was determined by the occurrence of either death, ipsilateral stroke, or ipsilateral bypass surgery. Stroke was defined as any neurological deficit including transient symptoms resolving completely within 24 hours. Ipsilateral bypass surgery was defined as ECIIC arterial bypass for the lesion previously treated by PTCBA. Repeated PTCBA was defined as a repeated percutaneous intervention involving the previously treated lesion after the time of the initial procedure.
The main clinical analysis consisted of a comparison between the three groups classified by the angiographic lesions' characteristics with respect to the primary clinical end point.
Results
According to the angiographic lesion characteristics prior to PTCBA, the endovascular surgeon (TM) and the neurosurgeon classified patients into three groups before the angioplasty treatment: type A 62 group (n=12); type B group (n=21); and type C group (n=9). There were no differences in base-line characteristics except blood pressure between the three groups. There were many total occlusions in type B and C groups as a matter of course (p=0.017) 6 • The clinical success rates in type A , B and C lesions were 92% (11112), 86% (18121) and 33% (319), respectively (p=0.0032) and there were significant differences between type A and C (p=0.0021) and between type B and C (p=0.0023). Therefore, successful procedures are related to the angiographic characteristics of lesions prior to PTCBA. Overall angiographic and clinical success rates were 79 (33142) and 76 (32/42) percent, respectively. Ten patients were not clinically treated successfully. Consequently, 32 lesions in 32 patients were eligible for the angiographic follow-up.
Among the 12 patients with recurrent or crescendo TIAs. prior to PTCBA ( 4, 5 and 3 patients in type A, B and C groups, respectively), 10 had a clinically successful dilatation and their symptoms disappeared immediately and completely. However, the other 2 patients underwent superficial temporal arterymiddle cerebral artery (STA-MCA) bypass surgery following unsuccessful PTCBA.
Angiographic restenosis rates in type A , B and C groups were 0% (0111), 33% (6118) and 100% (313) at one year (p=0.0027) and there was a significant difference between type A and C (p=0.0008). Angiographic restenosis rate in patients suffering from crescendo TIAs before PTCBA was only 10% (1/10) at one year, and the rate in patients with a minor stroke prior to PTCBA 36% (8122) at one year (p=0.21). Overall angiographic restenosis rate was 28% (9132) at one year.
Cumulative risks of fatal or nonfatal ipsilateral ischaemic stroke in type A , B and C groups were 8% , 12% and 56% at one and two years (p=0.1647). Fatal or nonfatal ipsilateral stroke I ipsilateral bypass surgery risks in type A, B and C groups were 8%, 26% and 87% at one and two years (p < 0.0001) and there were significant differences between type A and C (p=0.0005) and between type B and C (p=0.0001).
Fatal or nonfatal ipsilateral stroke I ipsilateral bypass surgery I repeated PTCBA risks in type A, B and C groups were 8%,42% and 100% at one and two years (p<0.0001) and there were significant differences between type A and C (p=0.0001) and between type B and C (p<0.0001), although the difference between type A and B was not significant (p=0.0657).
No patients exhibited a major ischaemic stroke following the successful PTCBA treatment. Overall cumulative risks of fatal or nonfatal ipsilateral stroke and fatal or nonfatal ipsilateral ischaemic stroke I ipsilateral bypass surgery were 14 and 33 percent at one and two years, respectively.
Discussion
Some previous studies 7-13, which include various grades of stenosis (low-grade to high-grade), report the clinical outcome of medically treated patients with intracranial arterial stenosis, in contrast to the clinical outcome for high-grade stenosis(> 70%) only in the present study. Whilst regarding the great difference in the angiographic characteristics between historical controls and the present study, the clinical outcome must be compared.
We defined stroke as any neurological deficit including a TIA and recalculated cumulative stroke risk by Kaplan-Meier method based on data described in some previous studies 8 • 9 • 11 • In the historical controls, cumulative stroke risk ranged from 8 to 100% at 2 years and many studies reported a 13% to 22% ischaemic stroke risk at two years.
The cumulative risk of fatal or nonfatal ipsilateral stroke and ipsilateral stroke I bypass surgery was only 8 percent at two years in type A group, and this seemed to be smaller than in the historical controls. Although there is no statistical difference in fatal or nonfatal ipsilateral stroke risk between the three groups (type A-C), it can be a type II statistical error due to the small population in the present study.
There were significant differences in cumulative risks of ipsilateral stroke I bypass surgery and ipsilateral stroke I bypass surgery I repeated PTCBA between the 3 groups and the risk of cerebral events was the smallest in type A group, although the difference between type A and B is not significant and could be a type II error.
Type A lesions were found to be related to a high success rate and a low cerebral event risk and therefore are the most successfully responsive to cerebral balloon angioplasty and thus PTCBA in type A lesions seems to be an appropriate treatment. In contrast, the high incidence of fatal or nonfatal ipsilateral stroke I bypass surgery found in type C lesions following PTCBA suggests that PTCBA should not be attempted on type C lesions.
The outcome of PTCBA for type B lesions remains controversial. In the present study, 10 out of 12 patients presenting crescendo TIAs prior to PTCBA were successfully treated and their symptoms actually ceased completely after successful dilatation, although two patients in type C group underwent bypass surgery after unsuccessful PTCBA. This suggests that antegrade revascularisation by PT CBA has a great efficacy in improving perfusion to the affected territory and thus the authors expect that PTCBA can be effective in treating patients who suffer from crescendo TIAs or impending stroke.
In the type A group, the angiographic restenosis rate following PTCBA was 0% at one year. On consideration that coronary angioplasty is common world-wide despite a restenosis rate ranging from 30 to 50%, the overall restenosis rate of 28% following Rivista di Neuroradiologia 12 (Suppl 2), 1999 PTCBA seems to be acceptable. The success rate and clinical outcome for the type A group is encouraging and warrants further investigation and a randomised trial of PTCBA for intracranial atherosclerotic type A lesions.
Like carotid artery vertebral artery transluminal angioplasty study (CAVATAS 13), a randomised study is needed for medical and PTCBA techniques to assess the safety and efficacy of PTCBA therapy more accurately. Although repeatability is one of benefits of PTCBA, whether or not PTCBA should be repeated for restenosis prior to symptomatic recurrence is controversial, even though SPECT scans show lesions to be haemodynamically significant.
In conclusion, our results suggest that PTCBA for intracranial simple (type A) lesions produces a favourable clinical outcome for symptomatic patients.
